MCKESSON CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MCK in the last 30 days.
See all $MCK insider activity →Caribou Biosciences (CRBU) is exploring strategic alternatives, including a potential sale, and will discontinue two CAR-T therapy programs. Viatris (VTRS) agreed to acquire Pacira BioSciences for $1.65B. Uber (UBER) will buy ezCater for $2.3B. Skydance (SKYD) completed its acquisition of Warner Bros. Discovery (WBD). True Food Kitchen filed for Chapter 11 bankruptcy.
Leerink Partners maintained an Outperform rating for McKesson (MCK) and raised its price target from $1030 to $1070. The company's GF Value™ suggests it is 9.4% overvalued, while its GF Score™ is 80/100, indicating strong performance. McKesson, a major pharmaceutical distributor, has a market cap of $106.47B and generates over $350B in annual revenue.
Leerink Partners raised its price target for McKesson to $1,070 from $1,030. The stock has seen a 5-day change of 0.68%, a 1st Jan change of 6.57%, and a 12.36% increase overall. The adjustment is based on various composite ratings, including valuation and EPS revisions.
Over the past 7 days, AlphAI's AI scored 12 news stories mentioning MCK (MCKESSON CORP). Coverage has skewed bullish: 9 bullish, 3 neutral, and 0 bearish.
Recent MCK coverage spans mergers & acquisitions, financial news and corporate actions.
Expands McKesson's home‑health portfolio.
Analyst price target increase may support modest upside.
Analyst target raise suggests upside potential for the stock.
Participation in the acquisition could be viewed positively for McKesson's growth outlook.
McKesson may face modest downside or neutral impact as capital is allocated to the transaction.
AlphAI scores every news story that mentions MCK with an AI model for sentiment and relevance, and aggregates insider trades from MCKESSON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Caribou Biosciences (CRBU) is exploring strategic alternatives, including a potential sale, and will discontinue two CAR-T therapy programs. Viatris (VTRS) agreed to acquire Pacira BioSciences for $1.65B. Uber (UBER) will buy ezCater for $2.3B. Skydance (SKYD) completed its acquisition of Warner Bros. Discovery (WBD). True Food Kitchen filed for Chapter 11 bankruptcy.
3 min readLeerink Partners maintained an Outperform rating for McKesson (MCK) and raised its price target from $1030 to $1070. The company's GF Value™ suggests it is 9.4% overvalued, while its GF Score™ is 80/100, indicating strong performance. McKesson, a major pharmaceutical distributor, has a market cap of $106.47B and generates over $350B in annual revenue.
2 min readLeerink Partners raised its price target for McKesson to $1,070 from $1,030. The stock has seen a 5-day change of 0.68%, a 1st Jan change of 6.57%, and a 12.36% increase overall. The adjustment is based on various composite ratings, including valuation and EPS revisions.
1 min readJefferies downgraded Option Care Health (OPCH) to Hold from Buy with a new price target of $32.05, following an acquisition agreement at that price per share by CD&R and McKesson (MCK).
2 min readOption Care Health (OPCH) shares rose 34% after CD&R and McKesson (MCK) agreed to acquire the company for $32.05 per share, valuing it at $5.8B including debt. The deal is expected to close in 2024, subject to regulatory approval and OPCH shareholder approval.
1 min readOption Care Health, Inc. (OPCH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health NEW YORK, IRVING, Texas and BANNOCKBURN, Ill., October 6, 2026 — CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announc
2 min readMCKESSON CORP (MCK) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health NEW YORK, IRVING, Texas and BANNOCKBURN, Ill., October 6, 2026 — CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announc
2 min readMcKesson and private equity firm Clayton, Dubilier & Rice are in advanced talks to acquire Option Care Health, valuing the company at over $5B, including debt. Option Care Health provides medical infusion services.
1 min readOption Care Health (OPCH) shares rose 22% after hours on reports that McKesson and CD&R are in advanced talks to acquire it for over $5 billion, including debt. CD&R would hold 51%, McKesson 49%, with McKesson having future purchase rights. OPCH shares had fallen 27% year-to-date, with an enterprise value of $4.6 billion, including $1.2 billion in debt.
2 min readAccenture's (ACN) shares rose 15.8% after beating Q4 earnings estimates. Acuity (AYI) fell 3.4% missing revenue estimates. McKesson (MCK) gained 5.3% after reaffirming fiscal 2027 EPS guidance. Progress Software (PRGS) dropped 8.5% after missing Q3 revenue estimates.
2 min read